IMPORTANT MESSAGE – NeoLINK - Limited Functionality within Internet Explorer
As you may be aware, starting June 15, 2022, the Internet
Explorer 11 desktop application will no longer be supported by Microsoft. As a result, effective 04/25/2022,
NeoGenomics Laboratories will no longer ensure NeoLINK is compatible within
any version of Internet Explorer.
Customers using Internet Explorer may experience loss of functionality
while navigating throughout NeoLINK.
Customers are encouraged to move to Microsoft Edge, which
provides support for legacy and modern websites and apps. Google Chrome is also an acceptable and
supported alternative.
If you have any questions or concerns please contact
NeoGenomics Client Services at 866-776-5907, Option 3.
Thank you,
IT Development and Security, NeoGenomics Laboratories
5/18/22
Requirement of
NPI Number with Orders
Starting July 2022, NPI numbers
of both Ordering and Treating Physicians will be required on all orders with
NeoGenomics across all platforms (paper requisitions, online orders, and
interfaced orders). NPI numbers are important for report distribution and billing
accuracy. If possible, please make all necessary preparations by July 2022 to
ensure your orders will be completed with appropriate NPI numbers. Please stay
tuned for further info and reminders from your Neo Sales Consultants and
NeoNEWS. For any questions, please contact our Client Services team at
1.866.776.5907 option 3.
Molecular
FLT3 Testing
with NeoTYPE® Heme Profiles – Effective
Monday, June 6, FLT3 by PCR (via FLT3
Mutation Analysis) will be available to be ordered, as Client-Bill only,
in conjunction with the following NeoTYPE® Heme Profiles:
- NeoTYPE® AML Prognostic Profile
- NeoTYPE® MDS/CMML Profile
- NeoTYPE® Myeloid Disorders
Profile
It will be an additional test
order and reported separately from the NeoTYPE® Profile (which
includes the FLT3 gene by NGS). This test combination is intended to be used
for the purpose of prompt therapy selection in patients with a new diagnosis of
AML.
Ordering options will be
available as follows:
- NeoTYPE® AML Prognostic Profile
- NeoTYPE® AML Prognostic Profile
(plus FLT3 by PCR)
- NeoTYPE® MDS/CMML Profile
- NeoTYPE® MDS/CMML Profile (plus
FLT3 by PCR)
- NeoTYPE® Myeloid Disorders
Profile
- NeoTYPE® Myeloid Disorders
Profile (plus FLT3 by PCR)
Note: This new ordering structure will replace the current process
which, by default, includes preliminary FLT3 testing by PCR with all orders of
the aforementioned NeoTYPE® Profiles.
Please contact your local NeoGenomics Sales Consultant or our Client Services
team at 1.866.776.5907 option 3 for pricing.
Update to
NeoTYPE® Colorectal and Endometrial Profiles: Effective Monday, June 6th, MLH1 Promoter Methylation Analysis
will be removed from these two solid tumor profiles. Microsatellite instability
analysis and BRAF mutation analysis by NGS remain part of these profiles for
Lynch Syndrome assessment and interpretation, respectively. Options to follow
up MSI-high results include add-on MMR IHC and/or stand-alone MLH1 Promoter
Methylation Analysis.
This change is part of ongoing efforts to maintain efficiency in our
laboratory. No price or CPT code changes apply to the impacted NeoTYPE
Profiles.
For
interface-related test changes taking effect on Monday June 6th, click here
for a downloadable document to view the impacted interface test codes.
If you have interface questions, please contact InterfaceTeam@Neogenomics.com